Veterinary Medical Device Regulation: FDA CVM, EU Gaps, and Global Strategy

Veterinary Devices Exist in a Regulatory Gray Zone — Here Is How to Navigate It

The global veterinary equipment and disposables market was valued at approximately $7.8 billion in 2025 and is projected to reach $12.1 billion by 2034, growing at a 5.0% CAGR. The broader veterinary medicine market reached $38.2 billion in 2025, driven by rising pet ownership, increasing expenditure on animal healthcare, and technological innovation in diagnostic and therapeutic tools.

Yet for all this market growth, the regulatory framework for veterinary medical devices remains remarkably fragmented. Unlike veterinary drugs, which are subject to well-defined approval pathways (FDA New Animal Drug Applications in the US, EU veterinary medicinal product regulations), veterinary medical devices occupy an ambiguous space in most regulatory systems. There is no dedicated "veterinary device" classification at the FDA, and the EU has no harmonized framework for veterinary devices at all.

This creates both risk and opportunity. Companies that understand the regulatory landscape can move faster and with more confidence. Those that assume veterinary devices are regulated the same way as human devices — or that they are not regulated at all — face compliance failures, market access delays, and enforcement risk.

This guide explains the current state of veterinary medical device regulation across the US, EU, and key global markets, covering the FDA CVM framework, the EU classification gap, off-label use rules, and practical market entry strategy.

FDA Regulation of Veterinary Medical Devices

The Legal Framework: No Formal "Veterinary Device" Approval

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, or in-vitro reagent intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, or intended to affect the structure or function of the body of man or other animals.

This definition explicitly includes veterinary applications. However, FDA's Center for Veterinary Medicine (CVM) does not formally approve veterinary medical devices. As stated in the FDA's own guidance: "There is no formal approval of 'veterinary devices.' The Center for Veterinary Medicine (CVM) refers to those medical devices used exclusively for animals as veterinary devices, and these are subject to the general provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that relate to misbranding, mislabeling, and adulteration."

This means:

• No premarket approval is required for devices marketed exclusively for veterinary use
• No 510(k) submission is needed for veterinary-only devices
• No PMA is required, regardless of risk level
• Manufacturers must still comply with general provisions against adulteration and misbranding

What "General Provisions" Means in Practice

Although FDA does not require premarket approval for veterinary devices, manufacturers must comply with the following:

Off-Label Use: Using Human Devices in Animals

A critical practical issue is the use of human medical devices in veterinary practice. Section 1006 of the FD&C Act provides that nothing in the Act "shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship."

This means:

• Veterinarians may legally use human-approved medical devices off-label in animals
• A human 510(k)-cleared device can be used in veterinary practice without additional FDA authorization
• However, off-label use that causes food derived from a food-producing animal to be adulterated would still violate the FD&C Act
• FDA encourages veterinarians to consider off-label use carefully, especially when specifically contraindicated by the device's label

When a Veterinary Device Becomes a Drug

If a product achieves its primary intended purpose through chemical action or is metabolized by the animal's body, it is classified as a drug — not a device — regardless of how it is marketed. This is the same boundary test used for human products. Examples of products that may cross the device-drug boundary in veterinary medicine include:

• Implants that release therapeutic substances (drug-device combination products)
• Wound care products containing active pharmaceutical ingredients
• Products marketed with drug-like therapeutic claims

These products require a New Animal Drug Application (NADA) or Abbreviated NADA (ANADA) through FDA CVM, not just device-level compliance.

FDA CVM Innovation Agenda

FDA CVM announced its Animal and Veterinary Innovation Agenda, which includes:

• A Gene Editing Regulatory Science Council to evaluate emerging genetic technologies across human, animal, and plant programs
• A Priority Zoonotic Animal Drug (PZAD) designation to expedite products that address zoonotic diseases (e.g., anti-influenza treatments for livestock)
• An Innovation Exploration Task Force to monitor emerging technologies from all sectors
• Alignment with One Health principles, integrating human, animal, and environmental health objectives

While these initiatives focus primarily on drugs and biologics, they signal CVM's growing attention to the veterinary product landscape, and device manufacturers should monitor for potential future regulatory expansion.

EU Regulation of Veterinary Medical Devices

The EU Has No Harmonized Veterinary Device Framework

Unlike human medical devices — which are comprehensively regulated under EU MDR 2017/745 — veterinary medical devices have no dedicated EU-wide regulatory framework. A 2020 review published in the journal Animal Welfare (Cambridge University Press) found that only six out of 28 EU member states (Belgium, Croatia, Czech Republic, Germany, Hungary, and Slovakia) had any degree of regulation for veterinary devices.

This means that a single veterinary device product may be:

• Regulated as a veterinary medicinal product in one member state
• Regulated as a veterinary medical device in another
• Not regulated at all in a third

This patchwork creates significant uncertainty for manufacturers seeking EU-wide market access.

How Some Member States Handle Veterinary Devices

In member states with some degree of regulation, veterinary devices may be subject to:

What EU Market Access Means in Practice

For manufacturers selling veterinary devices in the EU:

1. No CE marking requirement — Veterinary devices do not fall under MDR, so CE marking for medical devices is not required (unless the device is also marketed for human use)

2. General product safety — The EU General Product Safety Directive (GPSD, 2001/95/EC) and its replacement, the General Product Safety Regulation (GPSR, Regulation (EU) 2023/988, effective December 2024), apply to all consumer products, including veterinary devices

3. Veterinary medicinal product regulation — If a device crosses the drug-device boundary (e.g., drug-eluting veterinary implants), it falls under the veterinary medicinal products framework (Directive 2001/82/EC, updated by Regulation (EU) 2019/6)

4. Electromagnetic compatibility — Devices with electronic components must comply with EU EMC Directive (2014/30/EU)

5. National requirements — Individual member states may impose additional registration or notification requirements

Global Regulatory Landscape

Key Markets for Veterinary Medical Devices

Veterinary Device Market by Segment

The veterinary equipment and disposables market is segmented into several key product categories:

• Patient monitoring equipment — Vital signs monitors, ECG, pulse oximeters for veterinary use
• Anesthesia equipment — Ventilators, vaporizers, breathing circuits designed for animal patients
• Diagnostic imaging — Veterinary X-ray, ultrasound, CT, MRI systems
• Surgical instruments — Electrosurgical units, endoscopes, orthopedic implants for animals
• Infusion pumps and IV systems — Calibrated for veterinary dosing requirements
• Consumables and disposables — Syringes, catheters, wound care products, gloves

North America dominates the veterinary equipment market with approximately 33% market share, followed by Europe. The Asia-Pacific region is the fastest-growing segment, driven by rising pet ownership in China, Japan, South Korea, and India.

Regulatory Strategy for Veterinary Device Manufacturers

Pathway Decision Framework

Best Practices for Compliance

1. Voluntary quality management — Even though ISO 13485 certification is not legally required for veterinary-only devices, implementing a quality management system provides competitive advantages, supports market access in multiple jurisdictions, and reduces product liability risk.

2. Robust labeling — Labeling must be truthful and not misleading. Avoid drug-like claims (e.g., "treats," "cures," "prevents disease") that could trigger drug classification. Use terms like "supports," "aids in," or "intended for use in."

3. Adverse event monitoring — Establish a post-market surveillance system to track device performance and safety in the field. While not mandatory, proactive monitoring demonstrates due diligence and supports product improvement.

4. Risk management documentation — Apply risk management principles (ISO 14971 provides a useful framework) to identify, evaluate, and mitigate risks associated with veterinary device use.

5. Biocompatibility testing — For devices that contact animal tissue, perform biocompatibility testing appropriate to the nature and duration of contact. ISO 10993 provides the standard framework, adapted for veterinary applications.

6. Electrical safety and EMC — For electromedical devices, comply with IEC 60601-1 (electrical safety) and IEC 60601-1-2 (EMC) to address safety risks from electrical and electromagnetic hazards.

The Human-Veterinary Regulatory Intersection

Many medical device companies serve both human and veterinary markets. Understanding the intersection is essential:

• Cross-market products — Devices like infusion pumps, pulse oximeters, and surgical instruments may be used in both human and veterinary settings. A single 510(k) clearance for human use can enable veterinary market access through off-label use provisions.

• Regulatory arbitrage — Some companies market devices exclusively for veterinary use to avoid the time and cost of FDA premarket review. While legally permissible, this strategy limits the product to veterinary channels and may create perception challenges with investors and partners.

• Adaptation requirements — Devices designed for human anatomy may require modifications (size, weight, material compatibility, dosage ranges) for veterinary applications. These modifications may affect the regulatory pathway if the device also maintains human-use claims.

• Combination products — Products that combine device and drug components face the most complex regulatory landscape. In the US, these are managed through FDA's Office of Combination Products (OCP), which determines whether CVM or CDRH has primary jurisdiction.

For manufacturers developing products that bridge both human and animal health, understanding the veterinary regulatory landscape is essential. Resources focused specifically on veterinary medicine and animal health regulation, such as VetMedGuide, which covers veterinary device classification and animal-drug regulatory pathways, can complement the human medical device regulatory guidance found on this site.

Key Takeaways

1. No formal FDA approval pathway exists for veterinary devices — they are subject to general anti-adulteration and anti-misbranding provisions, not 510(k) or PMA requirements.

2. The EU has no harmonized veterinary device framework — only six member states have any degree of regulation, creating a patchwork of national requirements.

3. Off-label use of human devices in veterinary practice is legal in the US, providing a practical pathway for manufacturers with existing FDA-clearanced products.

4. The device-drug boundary is critical — products with drug components or drug-like claims will be regulated as veterinary drugs, requiring NADA/ANADA approval.

5. Voluntary quality management and risk management provide competitive advantages and risk mitigation, even when not legally mandated.

6. The veterinary device market is growing at 5% CAGR globally, with North America and Asia-Pacific representing the largest opportunities.